کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10908626 | 1087793 | 2015 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ADAM28ROCRFSATOMRDB-ALLRT-PCREFsatRA - ATRAPI3K/Akt Pathway - PI3K / Akt Pathwayarsenic trioxide - آرسنیک تریاکسیدall-trans retinoic acid - آل – ترانس رتینوئیک اسیدEvent-free survival - بقاء بدون وقفهoverall survival - بقای کلELISA - تست الیزاEnzyme-linked immunosorbent assay - تست الیزاMinimal residual disease - حداقل بیماری باقی ماندهCNS - دستگاه عصبی مرکزیcomplete remission - رمی کاملrelapse-free survival - زنده ماندن بدون عودcentral nervous system - سیستم عصبی مرکزیB-cell acute lymphoblastic leukemia - لوسمی لنفوبلاستی حاد B-سلولیbone marrow - مغز استخوانreal-time quantitative polymerase chain reaction - واکنش زنجیره ای پلیمراز کمی زمان واقعی استreceiver operating characteristics - ویژگی های عملکرد گیرندهprognosis - پیش شناخت بیماری
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
B-cell acute lymphoblastic leukemia (B-ALL) in adults is a very challenging disease. Relapse following remission after induction chemotherapy remains the major barrier to patient survival. ADAM28 is overexpressed in several human tumors and is related to cell proliferation and lymph node metastasis. To date, no information has been available on the prognostic role of ADAM28 in B-ALL. Fifty consecutive patients with de novo B-ALL and 22 healthy donors were enrolled in this study and were followed for 2.8 years. Our data suggested that ADAM28 expression in B-ALL patients was significantly increased (PÂ <Â 0.0001). Patients experiencing disease relapse exhibited significantly increased ADAM28 expression, compared with those with favorable outcomes (PÂ =Â 0.0094). Notably, ADAM28 overexpression was associated with lower probabilities of relapse-free survival (RFS) and event-free survival (EFS) (PÂ <Â 0.001) and was a significant prognostic factor (PÂ <Â 0.001). In vitro, the PI3K/Akt pathway inhibitor, as well as arsenic trioxide (ATO), down-regulated ADAM28 expression. Our results were the first to indicate that ADAM28 overexpression in B-ALL patients is correlated with relapse. ADAM28 overexpression is potentially regulated by the PI3K/Akt pathway. These data demonstrate that ADAM28 might serve as a novel biomarker for evaluating relapse in B-ALL and as a potential therapeutic target in B-ALL patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 39, Issue 11, November 2015, Pages 1229-1238
Journal: Leukemia Research - Volume 39, Issue 11, November 2015, Pages 1229-1238
نویسندگان
Xiao-Hui Zhang, Chen-Cong Wang, Qian Jiang, Shen-Miao Yang, Hao Jiang, Jin Lu, Qian-Ming Wang, Fei-Er Feng, Xiao-Lu Zhu, Ting Zhao, Xiao-Jun Huang,